Jeff Yass’s BeOne Medicines Ltd ONC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.13M | Sell |
7,461
-7,347
| -50% | -$2.16M | ﹤0.01% | 6350 |
|
|
2026
Q1 | $4.4M | Buy |
14,808
+11,291
| +321% | +$3.65M | ﹤0.01% | 4471 |
|
|
2025
Q4 | $1.07M | Buy |
+3,517
| New | +$1.15M | ﹤0.01% | 7031 |
|
|
2025
Q1 | – | Sell |
-11,678
| Closed | -$2.73M | – | 13693 |
|
|
2024
Q4 | $2.16M | Buy |
11,678
+8,636
| +284% | +$1.76M | ﹤0.01% | 5146 |
|
|
2024
Q3 | $683K | Sell |
3,042
-8,052
| -73% | -$1.45M | ﹤0.01% | 7718 |
|
|
2024
Q2 | $1.58M | Buy |
+11,094
| New | +$1.71M | ﹤0.01% | 5557 |
|
|
2023
Q4 | – | Sell |
-7,849
| Closed | -$1.42M | – | 13459 |
|
|
2023
Q3 | $1.41M | Sell |
7,849
-11,663
| -60% | -$2.31M | ﹤0.01% | 5862 |
|
|
2023
Q2 | $3.48M | Buy |
+19,512
| New | +$4.49M | ﹤0.01% | 4123 |
|
|
2023
Q1 | – | Sell |
-8,441
| Closed | -$2.02M | – | 13654 |
|
|
2022
Q4 | $1.86M | Buy |
8,441
+6,305
| +295% | +$1.16M | ﹤0.01% | 4847 |
|
|
2022
Q3 | $288K | Buy |
+2,136
| New | +$367K | ﹤0.01% | 9898 |
|
|
2022
Q2 | – | Sell |
-1,356
| Closed | -$212K | – | 14141 |
|
|
2022
Q1 | $256K | Sell |
1,356
-174
| -11% | -$37K | ﹤0.01% | 10663 |
|
|
2021
Q4 | $415K | Buy |
1,530
+780
| +104% | +$263K | ﹤0.01% | 9672 |
|
|
2021
Q3 | $272K | Sell |
750
-2,524
| -77% | -$825K | ﹤0.01% | 10812 |
|
|
2021
Q2 | $1.12M | Buy |
3,274
+2,691
| +462% | +$891K | ﹤0.01% | 7444 |
|
|
2021
Q1 | $203K | Sell |
583
-4,895
| -89% | -$1.62M | ﹤0.01% | 11400 |
|
|
2020
Q4 | $1.42M | Sell |
5,478
-2,302
| -30% | -$634K | ﹤0.01% | 5865 |
|
|
2020
Q3 | $2.23M | Buy |
7,780
+4,530
| +139% | +$1.06M | ﹤0.01% | 4414 |
|
|
2020
Q2 | $612K | Sell |
3,250
-46,068
| -93% | -$7.5M | ﹤0.01% | 6941 |
|
|
2020
Q1 | $6.07M | Buy |
49,318
+35,939
| +269% | +$5.62M | ﹤0.01% | 2329 |
|
|
2019
Q4 | $2.22M | Sell |
13,379
-8,640
| -39% | -$1.44M | ﹤0.01% | 4146 |
|
|
2019
Q3 | $2.7M | Buy |
22,019
+10,695
| +94% | +$1.42M | ﹤0.01% | 3683 |
|
|
2019
Q2 | $1.4M | Buy |
+11,324
| New | +$1.44M | ﹤0.01% | 4922 |
|
|
2018
Q3 | – | Sell |
-24,569
| Closed | -$4.13M | – | 10407 |
|
|
2018
Q2 | $3.78M | Buy |
+24,569
| New | +$4.38M | ﹤0.01% | 3075 |
|
|
2018
Q1 | – | Sell |
-23,546
| Closed | -$3.19M | – | 10338 |
|
|
2017
Q4 | $2.3M | Buy |
+23,546
| New | +$2.16M | ﹤0.01% | 3656 |
|
|
2016
Q4 | – | Sell |
-14,758
| Closed | -$455K | – | 10271 |
|
|
2016
Q3 | $455K | Buy |
+14,758
| New | +$429K | ﹤0.01% | 6249 |
|
Other funds holding ONC
BBA
Jeff Yass's ONC Position: Q2 2026 in Review
Jeff Yass reduced its BeOne Medicines Ltd (ONC) stake by 50% in Q2 2026, selling an estimated $2.16M and leaving 7,461 shares worth $2.13M. The position accounts for ﹤0.01% of the portfolio, ranked #6350.
Jeff Yass first reported a position in ONC in Q3 2016 and has held it in 25 quarters since. The position peaked at $6.07M in Q1 2020. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.
- Jeff Yass held 7,461 shares of BeOne Medicines Ltd worth $2.13M as of Q2 2026.
- Jeff Yass sold 7,347 BeOne Medicines Ltd shares in Q2 2026, an estimated $2.16M.
- BeOne Medicines Ltd made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #6350 holding.
- Jeff Yass first reported a position in BeOne Medicines Ltd in Q3 2016 and has held it in 25 quarters since.
- Jeff Yass's BeOne Medicines Ltd position peaked at $6.07M in Q1 2020.
- 282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.